Key facts
- This page summarizes Jonathan E. Freeman's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Feb 2026, 08:00.
Jonathan E. Freeman - 05 Feb 2026 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)
- Reporting relationship
- Director
- Issuer ticker
- PHIO
- Reported as of
- 05 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Feb 2026, 08:00:21 UTC
- Prior SEC filing
- 15 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa C. Carson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jonathan E. Freeman filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 06 Feb 2026.
Change
- Previous filing in this sequence was filed on 15 Sep 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001708133
Primary reporting owner
Freeman Jonathan E
- Relationship
- Director
- Address
- C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA
- Signature
- /s/ Lisa C. Carson, Attorney-in-Fact
- Signature date
- 06 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHIO
transaction
Common Stock, $.0001 par value
Award
- Transaction value
- $0
- Shares
- +16,600
- Change %
- +103%
- Price
- $0.000000
- Shares after
- 32,655
- Date
- 05 Feb 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
Footnote F2
Includes shares of common stock underlying unvested restricted stock units.
Footnote F3
The number of reported securities has been adjusted to reflect prior reverse stock splits.